BlueBrainBoost
freedom-pharmacy
Purchases through the above links give commission which helps fund this website
Recent literature: SGLT-2 inhibitor
Date Journal Article title
2019 Apr Diabetes Obes Metab Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors and cancer: A Meta-analysis Of Randomized Controlled Trials.
2019 Apr Diabetes Obes Metab Eligibility of patients with type 2 diabetes for SGLT-2 inhibitor cardiovascular outcomes trials: an assessment using the Diabetes Collaborative Registry.
2019 Apr BMJ Case Rep Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis.
2019 Mar J Diabetes Sci Technol A Case Report of Diabetic Ketoacidosis With Combined Use of a Sodium Glucose Transporter 2 Inhibitor and Hybrid Closed-Loop Insulin Delivery.
2019 Mar Diabetologia No direct effect of SGLT2 activity on glucagon secretion.
2019 Diabetes Care Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide.
2019 Mar Brain Sci Empagliflozin Ameliorates Type 2 Diabetes-Induced Ultrastructural Remodeling of the Neurovascular Unit and Neuroglia in the Female idbiidbi Mouse.
2019 Expert Opin Pharmacother An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes.
2019 Lancet Diabetes Endocrinol Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
2019 Feb Cardiovasc Diabetol Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
2019 Endocrinol Diabetes Metab Sodium-glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
2019 Feb Metabolism Beyond glycemic control: New guidance on cardio-renal protection.
2019 Cell Physiol Biochem Effects of the SGLT-2 Inhibitor Canagliflozin on Adenine-Induced Chronic Kidney Disease in Rats.
2019 Feb World J Diabetes SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review.
2019 Diabetes Metab Syndr Obes Canagliflozin review - safety and efficacy profile in patients with T2DM.
2019 Feb Curr Med Res Opin The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
2019 Feb Acta Cardiol Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.
2019 Feb Curr Drug Saf Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus.
2019 Expert Rev Endocrinol Metab Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes.
2019 Jan Prim Care Diabetes Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
2019 Diabetes Obes Metab FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
2019 Jan J Diabetes Investig Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).
2019 Jan Curr Diab Rep Mineralocorticoid Antagonism and Diabetic Kidney Disease.
2019 CEN Case Rep Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor.
2018 J Pancreat Cancer Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy.
2019 J Clin Med Res Residual Effect of Sodium Glucose Cotransporter 2 Inhibitor, Tofogliflozin, on Body Weight After Washout in Japanese Men With Type 2 Diabetes.
2018 Curr Pharm Biotechnol Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations.
2018 Nov Circulation 24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study.
2019 Endocr Metab Immune Disor... The Possible Effects of Dapagliflozin on 12-derived Electrocardiogram in Patients with Type 2 Diabetes Mellitus.
2018 Diabetol Metab Syndr Evaluating the Diabetes-Cardiology interface: a glimpse into the diabetes management of cardiology inpatients in western Sydney's 'diabetes hotspot' and the establishment of a novel model of care.
2019 Jan Clin J Am Soc Nephrol Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.
2019 Biomed Pharmacother SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by pressing the activity of SGLT-2.
2018 Clin Kidney J The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
2019 Ann Pharmacother Ertugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus.
2019 Ann Pharmacother Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes.
2015 Oct Pharmacoeconomic Review R...
2019 Mol Metab SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
2018 Nov Curr Diab Rep The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes.
2018 Int J Endocrinol Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis.
2018 Cardiovasc Drugs Ther Dapagliflozin Attenuates Na+H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation.
2018 J Community Hosp Intern M... Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use.
2017 Sep New Drugs for Type 2 Diab...
2018 Oct Drug Res (Stuttg) Effect of Canagliflozin on Heart Function Involving Ketone Bodies in Patients with Type 2 Diabetes.
2018 Oct JAMA Rare Infection Linked With SGLT-2 Inhibitor Use.
2018 Obes Rev Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms.
2018 Nov Eur J Pharmacol Precision medicine approach: Empagliflozin for diabetic cardiomyopathy in mice with aldehyde dehydrogenase (ALDH) 2 * 2 mutation, a specific genetic mutation in millions of East Asians.
2018 Ther Clin Risk Manag Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes.
2018 Endokrynol Pol A review of cardiovascular outcome trials in type 2 diabetes.
2018 Diabetes Ther Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
2018 JACC Heart Fail Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
2018 Sep Ann Intern Med Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With Diabetes Mellitus.
2018 Case Rep Endocrinol Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis.
2018 Aug Medchemcomm Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.
2018 Am J Emerg Med Euglisemic diabetic ketoacidotic coma caused by dapagliflozin.
2019 Pharmacol Ther Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts.
2018 J Sex Med The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes.
2018 Diabetologia The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
2018 J Clin Med Res Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study.
2018 Sep JAMA Intern Med Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
2018 Diabetes Obes Metab Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?
2018 Expert Opin Drug Saf The safety of empagliflozin plus metformin for the treatment of type 2 diabetes.
2019 Diabetes Obes Metab Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case-control study.
2018 Kidney Int A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
2018 Diabetes Obes Metab Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes.
2019 Diabetes Obes Metab Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
2018 Biomed Pharmacother Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.
2018 Jul BMC Med Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink.
2018 Expert Opin Pharmacother Non-insulin pharmacological therapies for treating type 1 diabetes.
2018 Intern Med J Making sense of newer treatment options for type 2 diabetes.
2018 Expert Opin Drug Saf The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies.
2018 Eur Rev Med Pharmacol Sci The effects of a sodium-glucose cotransporter 2 inhibitor on diabetic nephropathy and serum oxidized low-density lipoprotein levels.
2018 Eur Endocrinol The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data.
2018 Endocrinol Diabetes Metab... Prolonged diabetic ketoacidosis associated with canagliflozin.
2018 Am Heart J The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
2018 Diabetes Care Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).